![](/img/cover-not-exists.png)
42PPrediction of PFS using a dynamic assessment of ctDNA in patients with EGFR mutated NSCLC with osimertinib therapy
Moiseenko, F, Stepanova, M, Zhabina, A, Myslik, A, Klimenko, V, Rysev, N, Artemieva, E, Shelekhova, K, Bogdanov, A, Volkov, N, Moiseenko, VVolume:
30
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdz413.047
Date:
November, 2019
File:
PDF, 74 KB
english, 2019